Drug & intervention

ferric carboxymaltose

RxCUI 1433693

Clinical trials15
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

15 shown
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV ApproachesNCT07053475 · 2025-04-02
TERMINATED
Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection FractionNCT05477498 · 2021-12-01
WITHDRAWN
Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart FailureNCT03871699 · 2019-08-30
UNKNOWN
Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection FractionNCT04974021 · 2019-06-20
UNKNOWN
Iron in Patients With Cardiovascular DiseaseNCT03991000 · 2019-02-28
TERMINATED
Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization TherapyNCT03380520 · 2017-10-01
COMPLETED
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron DeficiencyNCT03218384 · 2017-09-07
TERMINATED
Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)NCT03833336 · 2017-08-23
COMPLETED
A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.NCT03191201 · 2017-06-21
TERMINATED
Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron DeficiencyNCT02937454 · 2017-04-03
COMPLETED
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyNCT03037931 · 2017-03-15
COMPLETED
Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiencyNCT03079518 · 2017-03-10
COMPLETED
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)NCT02125344 · 2014-12-01
COMPLETED
Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric CarboxymaltoseNCT01978028 · 2013-10-01
TERMINATED
Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron DeficiencyNCT01513369 · 2012-08-01
COMPLETED

Conditions being studied

Heart Failure5Iron Deficiency4Iron-deficiency4Heart Failure With Normal Ejection Fraction2Heart Failure, Systolic2Systolic Heart Failure2Acute Myocardial Infarction1Anemia, Iron-deficiency1Arrhythmias, Cardiac1Atrial Fibrillation1Breast Cancer Female NOS1Cardiac Failure1Cardiovascular Diseases1Ferric Carboxymaltose1Ferropenic Anemia1Glucose Metabolism Disorders (Including Diabetes Mellitus)1Heart Failure With Preserved Ejection Fraction (HFPEF)1Heart Failure With Reduced Ejection Fraction1Heart Failure With Reduced Ejection Fraction (HFrEF)1HER2 Positive Breast Cancer1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.